Compare FANG & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FANG | KVUE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Specialty Chemicals |
| Sector | Energy | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.9B | 39.9B |
| IPO Year | 2012 | 2023 |
| Metric | FANG | KVUE |
|---|---|---|
| Price | $157.01 | $17.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $187.72 | $20.31 |
| AVG Volume (30 Days) | 1.6M | ★ 37.7M |
| Earning Date | 11-03-2025 | 11-03-2025 |
| Dividend Yield | 2.55% | ★ 4.79% |
| EPS Growth | N/A | ★ 35.31 |
| EPS | ★ 14.37 | 0.75 |
| Revenue | $14,626,000,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $43.41 | N/A |
| Revenue Next Year | N/A | $2.81 |
| P/E Ratio | ★ $10.91 | $23.18 |
| Revenue Growth | ★ 59.73 | N/A |
| 52 Week Low | $114.00 | $14.02 |
| 52 Week High | $180.91 | $25.17 |
| Indicator | FANG | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 60.90 |
| Support Level | $155.67 | $16.70 |
| Resistance Level | $160.86 | $17.59 |
| Average True Range (ATR) | 4.09 | 0.31 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 63.25 | 76.29 |
Diamondback is a crude oil and natural gas exploration and production firm whose operations represent a pure-play in the US Permian Basin. The company went public in 2012 and has established itself as a top-tier independent producer through disciplined acquisition and operational excellence. The company's most transformational transaction occurred in September 2024 with the completion of its $26 billion merger with Endeavor Energy Resources, which added around 470,000 net acres and doubled Diamondback's total acreage position. Diamondback boasts an enviable position in the Midland sub-basin, with some of the lowest unit costs among its Permian peers.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.